308846-66-4Relevant academic research and scientific papers
N-Phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATP Competitive DNA Gyrase B Inhibitors: Design, Synthesis, and Evaluation
Zidar, Nace,Macut, Helena,Toma?i?, Tihomir,Brvar, Matja?,Montalv?o, Sofia,Tammela, P?ivi,Solmajer, Tom,Peterlin Ma?i?, Lucija,Ila?, Janez,Kikelj, Danijel
supporting information, p. 6179 - 6194 (2015/08/24)
Bacterial DNA gyrase is a well-known and validated target in the design of antibacterial drugs. However, inhibitors of its ATP binding subunit, DNA gyrase B (GyrB), have so far not reached clinical use. In the present study, three different series of N-ph
SYNTHESIS OF OXAZOLINE COMPOUNDS
-
Page/Page column 12; 18-19, (2010/04/03)
The present invention provides an improved process for preparing an oxazoline compound of the formula: (I) wherein R1 and R2 are independently hydrogen, sulfide, sulfoxide, sulfonyl, optionally substituted lower alkyl, optionally sub
Structure-activity relationship of new anti-tuberculosis agents derived from oxazoline and oxazole benzyl esters
Moraski, Garrett C.,Chang, Mayland,Villegas-Estrada, Adriel,Franzblau, Scott G.,M?llmann, Ute,Miller, Marvin J.
experimental part, p. 1703 - 1716 (2010/06/19)
During the syntheses and studies of natural iron chelators (mycobactins), we serendipitously discovered that a simple, small molecule, oxazoline-containing intermediate 3 displayed surprising anti-tuberculosis activity (MIC of 7.7?μM, average). Herein we
Constrained analogues of procaine as novel small molecule inhibitors of DNA methyltransferase-1
Castellano, Sabrina,Kuck, Dirk,Sala, Marina,Novellino, Ettore,Lyko, Frank,Sbardella, Gianluca
, p. 2321 - 2325 (2008/12/22)
Constrained analogues of procaine were synthesized, and their inhibiting activity against DNMT1 was tested. Among them, the most potent compound, derivative 3b, was also able to induce a recognizable demethylation of chromosomal satellite repeats in HL60 human myeloid leukemia cells and thus represents a lead compound for the development of a novel class of non-nucleoside DNMT1 inhibitors.
